Brianne Bettcher
Concepts (304)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 31 | 2026 | 622 | 6.390 |
Why?
| | White Matter | 8 | 2023 | 154 | 2.640 |
Why?
| | Aging | 21 | 2026 | 1966 | 2.090 |
Why?
| | Cognition Disorders | 13 | 2023 | 538 | 1.700 |
Why?
| | Inflammation | 9 | 2026 | 2880 | 1.660 |
Why?
| | Neuropsychological Tests | 27 | 2026 | 1137 | 1.590 |
Why?
| | Cognitive Dysfunction | 14 | 2026 | 464 | 1.450 |
Why?
| | Cognition | 13 | 2025 | 1269 | 1.380 |
Why?
| | Memory, Episodic | 4 | 2021 | 54 | 1.330 |
Why?
| | Dementia | 10 | 2024 | 304 | 1.270 |
Why?
| | Activities of Daily Living | 8 | 2021 | 441 | 1.250 |
Why?
| | Aged, 80 and over | 40 | 2026 | 8279 | 1.210 |
Why?
| | Executive Function | 10 | 2021 | 461 | 1.090 |
Why?
| | Psychomotor Performance | 7 | 2021 | 328 | 1.040 |
Why?
| | Signal Detection, Psychological | 3 | 2011 | 25 | 0.970 |
Why?
| | Aged | 58 | 2026 | 25947 | 0.950 |
Why?
| | Biomarkers | 12 | 2026 | 4275 | 0.940 |
Why?
| | Gliosis | 2 | 2023 | 29 | 0.870 |
Why?
| | Brain | 14 | 2024 | 2941 | 0.800 |
Why?
| | Neurology | 1 | 2025 | 114 | 0.790 |
Why?
| | Encephalitis | 3 | 2014 | 142 | 0.780 |
Why?
| | Inflammation Mediators | 1 | 2025 | 509 | 0.720 |
Why?
| | Health Status | 2 | 2026 | 836 | 0.710 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2025 | 125 | 0.700 |
Why?
| | Memory Consolidation | 1 | 2021 | 14 | 0.690 |
Why?
| | Biofeedback, Psychology | 2 | 2011 | 35 | 0.680 |
Why?
| | Atrophy | 8 | 2024 | 201 | 0.650 |
Why?
| | Healthy Aging | 1 | 2021 | 40 | 0.650 |
Why?
| | Temporal Lobe | 4 | 2021 | 104 | 0.640 |
Why?
| | Diffusion Tensor Imaging | 5 | 2023 | 73 | 0.630 |
Why?
| | Memory, Short-Term | 4 | 2019 | 271 | 0.630 |
Why?
| | Immune System | 1 | 2021 | 179 | 0.630 |
Why?
| | Interleukin-6 | 4 | 2026 | 780 | 0.620 |
Why?
| | Fornix, Brain | 1 | 2019 | 5 | 0.610 |
Why?
| | Cognitive Reserve | 1 | 2019 | 15 | 0.600 |
Why?
| | Middle Aged | 41 | 2026 | 35928 | 0.590 |
Why?
| | Neurogenesis | 1 | 2021 | 157 | 0.580 |
Why?
| | Astrocytes | 1 | 2021 | 224 | 0.580 |
Why?
| | Neurodegenerative Diseases | 2 | 2012 | 151 | 0.550 |
Why?
| | Frontotemporal Dementia | 4 | 2024 | 57 | 0.550 |
Why?
| | Memory | 7 | 2014 | 296 | 0.540 |
Why?
| | Anisotropy | 5 | 2021 | 75 | 0.530 |
Why?
| | Humans | 75 | 2026 | 144957 | 0.520 |
Why?
| | Autoimmune Diseases of the Nervous System | 2 | 2014 | 31 | 0.520 |
Why?
| | Corpus Callosum | 2 | 2014 | 72 | 0.520 |
Why?
| | Male | 55 | 2026 | 72406 | 0.500 |
Why?
| | Memory Disorders | 2 | 2017 | 194 | 0.500 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 271 | 0.490 |
Why?
| | Female | 53 | 2026 | 78376 | 0.480 |
Why?
| | Magnetic Resonance Imaging | 19 | 2024 | 3869 | 0.480 |
Why?
| | Potassium Channels, Voltage-Gated | 3 | 2014 | 55 | 0.470 |
Why?
| | Cholesterol | 1 | 2017 | 408 | 0.430 |
Why?
| | Language Disorders | 1 | 2014 | 29 | 0.420 |
Why?
| | C-Reactive Protein | 2 | 2014 | 417 | 0.380 |
Why?
| | Brain Mapping | 1 | 2016 | 537 | 0.380 |
Why?
| | Prefrontal Cortex | 1 | 2016 | 328 | 0.370 |
Why?
| | Environment | 2 | 2011 | 305 | 0.360 |
Why?
| | Cerebral Cortex | 3 | 2022 | 465 | 0.350 |
Why?
| | Dementia, Vascular | 2 | 2008 | 21 | 0.340 |
Why?
| | tau Proteins | 6 | 2023 | 115 | 0.340 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2023 | 154 | 0.320 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 198 | 0.320 |
Why?
| | Advance Care Planning | 2 | 2025 | 243 | 0.320 |
Why?
| | Risk Factors | 7 | 2026 | 10792 | 0.290 |
Why?
| | Cohort Studies | 9 | 2020 | 5965 | 0.280 |
Why?
| | Mental Status Schedule | 4 | 2016 | 35 | 0.280 |
Why?
| | Reproducibility of Results | 6 | 2025 | 3415 | 0.270 |
Why?
| | Exosomes | 2 | 2020 | 104 | 0.270 |
Why?
| | Amyloid beta-Peptides | 3 | 2026 | 241 | 0.270 |
Why?
| | Verbal Learning | 4 | 2019 | 73 | 0.260 |
Why?
| | Parkinson Disease | 3 | 2026 | 600 | 0.250 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 19 | 0.240 |
Why?
| | Chemokine CXCL9 | 1 | 2026 | 38 | 0.240 |
Why?
| | Frontal Lobe | 2 | 2019 | 160 | 0.230 |
Why?
| | Apolipoproteins E | 4 | 2021 | 94 | 0.220 |
Why?
| | Cognitive Aging | 2 | 2023 | 18 | 0.220 |
Why?
| | Body Mass Index | 1 | 2013 | 2438 | 0.220 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 161 | 0.220 |
Why?
| | DNA Transposable Elements | 1 | 2025 | 122 | 0.210 |
Why?
| | Pilot Projects | 2 | 2021 | 1890 | 0.210 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 9 | 0.210 |
Why?
| | Video Recording | 1 | 2025 | 213 | 0.200 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2118 | 0.200 |
Why?
| | Neurons | 2 | 2025 | 1642 | 0.190 |
Why?
| | Neurites | 1 | 2023 | 50 | 0.190 |
Why?
| | Neuroimaging | 2 | 2023 | 292 | 0.190 |
Why?
| | Interferon-gamma | 1 | 2026 | 784 | 0.190 |
Why?
| | Cross-Over Studies | 1 | 2025 | 601 | 0.190 |
Why?
| | Blood-Brain Barrier | 1 | 2023 | 155 | 0.180 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 5872 | 0.170 |
Why?
| | Amnesia | 4 | 2014 | 47 | 0.170 |
Why?
| | Apolipoprotein E4 | 1 | 2021 | 41 | 0.170 |
Why?
| | Central Nervous System | 1 | 2023 | 281 | 0.160 |
Why?
| | Ultracentrifugation | 1 | 2020 | 51 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 685 | 0.160 |
Why?
| | Reaction Time | 2 | 2015 | 438 | 0.160 |
Why?
| | Sleep, REM | 1 | 2020 | 44 | 0.160 |
Why?
| | Proteins | 3 | 2016 | 1022 | 0.160 |
Why?
| | Medication Therapy Management | 1 | 2021 | 73 | 0.160 |
Why?
| | Longevity | 1 | 2021 | 173 | 0.160 |
Why?
| | Patient Care Team | 1 | 2025 | 689 | 0.150 |
Why?
| | Computational Biology | 1 | 2024 | 681 | 0.150 |
Why?
| | Attention | 2 | 2016 | 458 | 0.150 |
Why?
| | Speech Disorders | 1 | 2019 | 29 | 0.150 |
Why?
| | Lewy Body Disease | 1 | 2020 | 33 | 0.150 |
Why?
| | Software | 1 | 2024 | 692 | 0.150 |
Why?
| | Hearing Loss | 1 | 2023 | 247 | 0.150 |
Why?
| | Leukoaraiosis | 2 | 2009 | 2 | 0.150 |
Why?
| | Myelin Sheath | 1 | 2021 | 168 | 0.140 |
Why?
| | Gray Matter | 1 | 2019 | 92 | 0.140 |
Why?
| | Educational Status | 1 | 2021 | 467 | 0.140 |
Why?
| | Myocardial Contraction | 1 | 2020 | 298 | 0.140 |
Why?
| | Chemokine CCL4 | 1 | 2018 | 31 | 0.140 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2017 | 541 | 0.140 |
Why?
| | Chemokine CCL3 | 1 | 2018 | 26 | 0.140 |
Why?
| | Electroencephalography | 1 | 2021 | 551 | 0.140 |
Why?
| | Severity of Illness Index | 9 | 2016 | 2925 | 0.140 |
Why?
| | Research | 1 | 2021 | 431 | 0.140 |
Why?
| | Adult | 8 | 2026 | 40506 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2025 | 923 | 0.140 |
Why?
| | Neurogranin | 1 | 2017 | 2 | 0.130 |
Why?
| | Hippocampus | 2 | 2021 | 967 | 0.130 |
Why?
| | Primary Progressive Nonfluent Aphasia | 2 | 2013 | 2 | 0.130 |
Why?
| | Cytokines | 2 | 2018 | 2065 | 0.130 |
Why?
| | Functional Laterality | 2 | 2019 | 241 | 0.130 |
Why?
| | Mental Recall | 3 | 2017 | 222 | 0.130 |
Why?
| | Regression Analysis | 3 | 2020 | 1003 | 0.120 |
Why?
| | Autoantibodies | 2 | 2014 | 1504 | 0.120 |
Why?
| | Disease Progression | 3 | 2026 | 2852 | 0.120 |
Why?
| | Neuropsychiatry | 1 | 2016 | 17 | 0.120 |
Why?
| | Algorithms | 1 | 2024 | 1839 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2018 | 1217 | 0.120 |
Why?
| | Time Factors | 3 | 2014 | 7183 | 0.120 |
Why?
| | Hypolipidemic Agents | 1 | 2017 | 88 | 0.120 |
Why?
| | Random Allocation | 1 | 2017 | 363 | 0.120 |
Why?
| | Heart Rate | 1 | 2020 | 855 | 0.120 |
Why?
| | Chemokine CCL11 | 1 | 2015 | 25 | 0.120 |
Why?
| | Models, Anatomic | 1 | 2016 | 84 | 0.110 |
Why?
| | Telemedicine | 1 | 2025 | 948 | 0.110 |
Why?
| | Language | 3 | 2025 | 323 | 0.110 |
Why?
| | Amyloid | 1 | 2016 | 92 | 0.110 |
Why?
| | Factor Analysis, Statistical | 1 | 2016 | 293 | 0.110 |
Why?
| | Plaque, Amyloid | 1 | 2014 | 19 | 0.110 |
Why?
| | Triglycerides | 1 | 2017 | 521 | 0.110 |
Why?
| | Models, Neurological | 2 | 2024 | 254 | 0.110 |
Why?
| | Age Factors | 2 | 2025 | 3335 | 0.110 |
Why?
| | Prodromal Symptoms | 1 | 2014 | 21 | 0.110 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2014 | 75 | 0.110 |
Why?
| | Carotid Artery Diseases | 1 | 2014 | 69 | 0.110 |
Why?
| | Sleep | 1 | 2021 | 901 | 0.100 |
Why?
| | Communication | 1 | 2021 | 967 | 0.100 |
Why?
| | Nanoparticles | 1 | 2020 | 520 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 97 | 0.100 |
Why?
| | Aphasia, Broca | 1 | 2013 | 3 | 0.100 |
Why?
| | Bradycardia | 1 | 2014 | 59 | 0.100 |
Why?
| | Retina | 1 | 2016 | 324 | 0.100 |
Why?
| | Aphasia, Primary Progressive | 1 | 2013 | 2 | 0.100 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2013 | 18 | 0.100 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2013 | 19 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 6053 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2017 | 378 | 0.100 |
Why?
| | Prions | 1 | 2013 | 50 | 0.100 |
Why?
| | Proteomics | 1 | 2020 | 1195 | 0.100 |
Why?
| | Language Development Disorders | 1 | 2013 | 40 | 0.100 |
Why?
| | Animals | 4 | 2025 | 38109 | 0.100 |
Why?
| | Quality of Life | 1 | 2025 | 3192 | 0.100 |
Why?
| | Pacemaker, Artificial | 1 | 2014 | 126 | 0.100 |
Why?
| | Brain Diseases | 1 | 2014 | 153 | 0.100 |
Why?
| | Point Mutation | 1 | 2013 | 243 | 0.090 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 93 | 0.090 |
Why?
| | Colorado | 1 | 2022 | 4564 | 0.090 |
Why?
| | Linear Models | 1 | 2014 | 854 | 0.090 |
Why?
| | Heart Failure | 1 | 2025 | 2323 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2014 | 255 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2016 | 781 | 0.080 |
Why?
| | Apraxias | 3 | 2019 | 6 | 0.080 |
Why?
| | Statistics as Topic | 1 | 2011 | 284 | 0.080 |
Why?
| | Glucose | 1 | 2016 | 1049 | 0.080 |
Why?
| | Young Adult | 3 | 2025 | 14126 | 0.080 |
Why?
| | Down Syndrome | 1 | 2017 | 534 | 0.080 |
Why?
| | Comprehension | 2 | 2012 | 180 | 0.080 |
Why?
| | Macrophages | 1 | 2018 | 1511 | 0.080 |
Why?
| | Psychomotor Disorders | 1 | 2010 | 15 | 0.080 |
Why?
| | Disability Evaluation | 2 | 2009 | 310 | 0.080 |
Why?
| | Serial Learning | 1 | 2009 | 8 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 947 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2018 | 1153 | 0.080 |
Why?
| | Hypertension | 2 | 2020 | 1264 | 0.070 |
Why?
| | Learning | 1 | 2013 | 452 | 0.070 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2947 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2365 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1721 | 0.070 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2008 | 47 | 0.070 |
Why?
| | Choice Behavior | 1 | 2010 | 178 | 0.070 |
Why?
| | Motor Skills | 1 | 2009 | 104 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2024 | 521 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2147 | 0.070 |
Why?
| | Prospective Studies | 3 | 2014 | 7997 | 0.070 |
Why?
| | Semantics | 1 | 2008 | 100 | 0.070 |
Why?
| | Goals | 1 | 2009 | 184 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 17101 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1172 | 0.060 |
Why?
| | Adolescent | 3 | 2025 | 22453 | 0.060 |
Why?
| | Peptide Fragments | 2 | 2023 | 699 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2015 | 1241 | 0.060 |
Why?
| | Cues | 1 | 2009 | 326 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1472 | 0.060 |
Why?
| | Dopamine | 1 | 2009 | 289 | 0.060 |
Why?
| | Child | 2 | 2025 | 22657 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.060 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2006 | 74 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 80 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 851 | 0.050 |
Why?
| | Analysis of Variance | 3 | 2012 | 1311 | 0.050 |
Why?
| | Cell Death | 1 | 2025 | 383 | 0.050 |
Why?
| | Antipsychotic Agents | 1 | 2006 | 214 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 405 | 0.050 |
Why?
| | Psychotic Disorders | 1 | 2006 | 186 | 0.050 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 16 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 120 | 0.050 |
Why?
| | Schizophrenia | 1 | 2006 | 446 | 0.040 |
Why?
| | Nerve Net | 1 | 2024 | 285 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2014 | 460 | 0.040 |
Why?
| | Chromatin | 1 | 2025 | 561 | 0.040 |
Why?
| | Vision Disorders | 1 | 2023 | 178 | 0.040 |
Why?
| | Chemical Precipitation | 1 | 2020 | 39 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 683 | 0.040 |
Why?
| | Diffusion | 1 | 2020 | 122 | 0.040 |
Why?
| | Cardiac Electrophysiology | 1 | 2020 | 21 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1026 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2021 | 514 | 0.040 |
Why?
| | Facial Expression | 1 | 2019 | 74 | 0.040 |
Why?
| | Language Tests | 2 | 2009 | 23 | 0.040 |
Why?
| | Machine Learning | 1 | 2024 | 587 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 280 | 0.040 |
Why?
| | Problem Solving | 2 | 2009 | 156 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 109 | 0.030 |
Why?
| | Apoptosis | 1 | 2025 | 2430 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5614 | 0.030 |
Why?
| | Nerve Degeneration | 1 | 2016 | 48 | 0.030 |
Why?
| | C9orf72 Protein | 1 | 2016 | 13 | 0.030 |
Why?
| | Risk Assessment | 1 | 2026 | 3676 | 0.030 |
Why?
| | Independent Living | 1 | 2017 | 114 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2018 | 310 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2018 | 395 | 0.030 |
Why?
| | Carbolines | 1 | 2016 | 35 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 40 | 0.030 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2015 | 55 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 136 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2016 | 119 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2016 | 162 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4569 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2015 | 119 | 0.030 |
Why?
| | Judgment | 1 | 2015 | 66 | 0.030 |
Why?
| | Primary Health Care | 1 | 2025 | 1734 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 113 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 271 | 0.030 |
Why?
| | Antigens, CD20 | 1 | 2014 | 35 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2015 | 264 | 0.030 |
Why?
| | Hyponatremia | 1 | 2014 | 43 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 343 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 277 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 551 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 583 | 0.020 |
Why?
| | Genetic Testing | 1 | 2016 | 482 | 0.020 |
Why?
| | Rituximab | 1 | 2014 | 210 | 0.020 |
Why?
| | Visual Perception | 1 | 2015 | 183 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 307 | 0.020 |
Why?
| | Pedigree | 1 | 2013 | 514 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2012 | 62 | 0.020 |
Why?
| | Caregivers | 2 | 2012 | 1049 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11799 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1835 | 0.020 |
Why?
| | Seizures | 1 | 2014 | 477 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2016 | 791 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 232 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1407 | 0.020 |
Why?
| | Blood Pressure | 1 | 2015 | 1769 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1660 | 0.020 |
Why?
| | Differential Threshold | 1 | 2008 | 5 | 0.020 |
Why?
| | Cerebral Ventricles | 1 | 2008 | 54 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3608 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2009 | 233 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2007 | 56 | 0.020 |
Why?
| | Wechsler Scales | 1 | 2007 | 59 | 0.020 |
Why?
| | Reading | 1 | 2008 | 136 | 0.020 |
Why?
| | Speech Perception | 1 | 2008 | 91 | 0.020 |
Why?
| | Benchmarking | 1 | 2008 | 188 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2006 | 26 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2006 | 18 | 0.020 |
Why?
| | Risperidone | 1 | 2006 | 29 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1500 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 372 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 4099 | 0.010 |
Why?
| | Blood Glucose | 1 | 2015 | 2330 | 0.010 |
Why?
| | Benzodiazepines | 1 | 2006 | 168 | 0.010 |
Why?
| | Motor Activity | 1 | 2009 | 722 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 783 | 0.010 |
Why?
| | Psychometrics | 1 | 2008 | 734 | 0.010 |
Why?
| | Outpatients | 1 | 2006 | 443 | 0.010 |
Why?
| | United States | 1 | 2020 | 15988 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2032 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 11695 | 0.010 |
Why?
| | Depression | 1 | 2007 | 1559 | 0.010 |
Why?
|
|
Bettcher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|